OSR Holdings, Inc. (NASDAQ:OSRH – Get Free Report) was the target of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 1,048,980 shares, a decrease of 38.1% from the July 15th total of 1,693,343 shares. Currently, 4.7% of the shares of the company are sold short. Based on an average daily volume of 705,294 shares, the days-to-cover ratio is presently 1.5 days.
Institutional Trading of OSR
A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP purchased a new stake in OSR Holdings, Inc. (NASDAQ:OSRH – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. Institutional investors own 55.30% of the company’s stock.
OSR Stock Performance
NASDAQ OSRH traded down $0.16 during trading hours on Tuesday, hitting $0.43. The company had a trading volume of 132,069,062 shares, compared to its average volume of 6,452,790. The firm has a market capitalization of $15.07 million, a price-to-earnings ratio of -1.29 and a beta of 0.55. OSR has a 52 week low of $0.25 and a 52 week high of $1.24. The firm has a 50 day simple moving average of $0.39 and a 200 day simple moving average of $0.47.
Analysts Set New Price Targets
Several research firms have recently issued reports on OSRH. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research report on Wednesday, June 24th. Wall Street Zen raised shares of OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Get Our Latest Analysis on OSR
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.
Further Reading
- Five stocks we like better than OSR
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
